Related Experiment Video

Updated: May 22, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Direct thrombin inhibitors in cardiovascular disease

Kyle A Arsenault1, Jack Hirsh, Richard P Whitlock

  • 1Michael G. DeGroote School of Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada. arsenault.ka@gmail.com

Nature Reviews. Cardiology
|May 2, 2012
PubMed

Insights

New direct thrombin inhibitors offer alternatives to traditional anticoagulants. This review examines the efficacy and safety of bivalirudin, argatroban, and dabigatran etexilate in cardiovascular and thrombotic diseases.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Established anticoagulants like heparin and warfarin have limitations.
  • Development of novel anticoagulants is crucial for managing thrombotic disorders.
  • Direct thrombin inhibitors represent a promising new class of anticoagulants.

Purpose of the Study:

  • To review the evidence on direct thrombin inhibitors.
  • To assess the efficacy and safety of parenteral and oral direct thrombin inhibitors.
  • To evaluate their role in cardiovascular and thrombotic diseases.

Main Methods:

  • Systematic review of randomized controlled trials.
  • Analysis of clinical data for bivalirudin and argatroban (parenteral).
  • Evaluation of dabigatran etexilate (oral) in cardiovascular settings.

Main Results:

  • Parenteral direct thrombin inhibitors show specific efficacy in certain thrombotic conditions.
  • Oral dabigatran etexilate demonstrates comparable efficacy to warfarin with a different safety profile.
  • Bleeding risk remains a key consideration for all anticoagulants.

Conclusions:

  • Direct thrombin inhibitors are valuable additions to the anticoagulant armamentarium.
  • Bivalirudin, argatroban, and dabigatran etexilate offer distinct therapeutic options.
  • Further research is needed to optimize their use in diverse patient populations.

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.